Research updates, FDA changes, and industry developments. No fluff, just facts.
A meta-analysis of 14 GLP-1 trials finds women consistently outpace men on weight loss, with the gap widening on stronger drugs. Early retatrutide reports from female users align with the data.
Recent clinical data shows the mitochondrial peptide increases ATP production by 42%, while user reports suggest rapid improvements in energy and mental clarity.
Access barriers grow as weight bias, liability concerns, and regulatory uncertainty drive provider hesitation around compounded semaglutide and tirzepatide.
Growing user reports suggest copper peptides may address inflammatory skin conditions through barrier repair and immune modulation.
Users reporting copper peptide interference with Adderall and other stimulants. Research shows copper can disrupt dopamine metabolism.
Six-month peptide cycle data shows 8.4 pounds of fat loss while maintaining lean muscle mass. Reddit user shares professional DEXA scan documentation.
Recent research links the mitochondrial peptide to cardiovascular activation. Users report elevated heart rate, chest tightness, and sleep disruption.
Recent reports show retatrutide causing sleep quality issues even with 8+ hours of sleep. Users report jaw clenching, higher heart rate, and lower sleep scores.
Scientists map atomic structure of acylated GLP-1/GIP analogue at 1.6 Å resolution, uncovering unique porous spiral design that could slash production costs.
New degradation study tracks potency loss across popular research peptides under different storage conditions. BPC-157 and TB-500 hit hardest by degradation.
Irish team develops dissolving films that could replace weekly injections for tirzepatide and semaglutide users. Early results show promise for needle-phobic patients.
Major new study pools data from 16 placebo-controlled trials. The results are eye-opening for anyone choosing between tirzepatide and semaglutide.
Bayesian network meta-analysis shows tirzepatide 10mg and 15mg deliver superior weight reduction compared to other GLP-1s.
The triple agonist peptide shows promise in Phase 2 trials, but questions remain about safety, availability, and real-world effectiveness.
FDA enforcement against 503B compounding pharmacies has shifted the landscape for peptide access. Here's what happened and what it means.
Animal studies show real promise, but human evidence remains limited. Here's what we actually know about healing peptides.
Reconstitution errors are the #1 peptide mistake. Here's how to calculate doses correctly and avoid dangerous errors.
Research shows real wound healing and tissue repair effects beyond cosmetic marketing claims. Here's what GHK-Cu actually does.
Real-world injury recovery protocols from the peptide community. What works, what doesn't, and what you should know.
Recent bioavailability studies challenge oral BPC-157 effectiveness. Here's what the data shows about injection vs oral administration.
New enforcement actions and regulatory changes are reshaping GLP-1 peptide access. Here's what happened and what it means.
Quality testing reveals massive variations in peptide purity and potency. Here's how to read COAs and spot fake testing documents.